公开(公告)号：US20190152977A1

公开(公告)日：2019-05-23

申请号：US16186490

申请日：2018-11-10

Applicant: Ning Xi ,  Minxiong Li ,  Ju Peng ,  Xiaobo Li ,  Tao Zhang ,  Haiyang Hu ,  Wuhong Chen ,  Changlin Bai ,  Donghua Ke ,  Peng Chen

Inventor： Ning Xi ,  Minxiong Li ,  Ju Peng ,  Xiaobo Li ,  Tao Zhang ,  Haiyang Hu ,  Wuhong Chen ,  Changlin Bai ,  Donghua Ke ,  Peng Chen

IPC: C07D487/04 ,  C07D471/04 ,  C07D401/14 ,  C07D498/04 ,  C07D513/04 ,  C07D491/048 ,  C07D495/04 ,  C07D407/14

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D401/14 ,  C07D407/14 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

公开(公告)号：US20170081338A1

公开(公告)日：2017-03-23

申请号：US15263503

申请日：2016-09-13

Applicant: Ning Xi ,  Weilong Dai ,  Minxiong Li ,  Wuhong Chen ,  Tao Zhang ,  Haiyang Hu ,  Xiaobo Li ,  Jun Liu ,  Tingjin Wang

Inventor： Ning Xi ,  Weilong Dai ,  Minxiong Li ,  Wuhong Chen ,  Tao Zhang ,  Haiyang Hu ,  Xiaobo Li ,  Jun Liu ,  Tingjin Wang

IPC: C07D493/04 ,  A61K31/506 ,  A61K45/06 ,  A61K31/5377

CPC classification number: C07D493/04 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

公开(公告)号：US20150274747A1

公开(公告)日：2015-10-01

申请号：US14670425

申请日：2015-03-27

Applicant: Ning Xi ,  Minxiong Li ,  Xiaobo Li ,  Weilong Dai ,  Tingjin Wang

Inventor： Ning Xi ,  Minxiong Li ,  Xiaobo Li ,  Weilong Dai ,  Tingjin Wang

IPC: C07D493/04 ,  A61K31/506 ,  A61K45/06

CPC classification number: C07D403/14 ,  A61K31/506 ,  A61K31/527 ,  A61K45/06 ,  C07D401/14 ,  C07D403/12 ,  C07D493/04

Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

公开(公告)号：US09004201B2

公开(公告)日：2015-04-14

申请号：US13832284

申请日：2013-03-15

Applicant: Ning Xi ,  Jianguo Zhao ,  Bingtuan Gao ,  Jing Xu ,  Matt Mutka ,  Li Xiao

Inventor： Ning Xi ,  Jianguo Zhao ,  Bingtuan Gao ,  Jing Xu ,  Matt Mutka ,  Li Xiao

IPC: B62D57/00 ,  B25J9/16 ,  B25J9/10

CPC classification number: B25J9/1682 ,  B25J9/104 ,  Y10S901/01

Abstract: A jumping robot is provided. In another aspect, a jumping robot weighs less than 50 grams, jumps at least 20 cm high and has a maximum linear dimension of 10 cm. A further aspect provides a robot that employs an electromagnetic actuator that actuates at least two of: jumping, steering, self-righting, and/or mid-air orientation control.

Abstract translation: 提供跳跃机器人。 在另一方面，跳跃机器人重量小于50克，跳跃至少20厘米高，最大直线尺寸为10厘米。 另一方面提供了一种使用致动器的电磁致动器的机器人，其致动：跳跃，转向，自对准和/或空中取向控制中的至少两个。

公开(公告)号：US20140234254A1

公开(公告)日：2014-08-21

申请号：US14181670

申请日：2014-02-15

Applicant: Ning Xi

Inventor： Ning Xi

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  A61K31/444

CPC classification number: C07D487/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

公开(公告)号：US08685983B2

公开(公告)日：2014-04-01

申请号：US13308310

申请日：2011-11-30

Applicant: Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessadro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

Inventor： Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessadro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

IPC: A61K31/497 ,  A61K31/5377 ,  A61K31/437 ,  A61K31/519 ,  A61K31/4184 ,  A61K31/501 ,  A61K31/4709 ,  A61K31/4365

CPC classification number: C07D413/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US08293897B2

公开(公告)日：2012-10-23

申请号：US12576375

申请日：2009-10-09

Applicant: Ning Xi

Inventor： Ning Xi

IPC: A61P35/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D491/107 ,  C07D493/10 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter—and/or intra—cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract translation: 本发明提供了可用于调节蛋白酪氨酸激酶活性和调节细胞间和/或细胞内信号传导的新型化合物。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该组合物治疗哺乳动物，特别是人类中过度增殖性疾病的方法。

公开(公告)号：US20120107275A1

公开(公告)日：2012-05-03

申请号：US13323692

申请日：2011-12-12

Applicant: Brian K. Albrecht ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

Inventor： Brian K. Albrecht ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

IPC: A61K31/5025 ,  A61K31/5377 ,  C07D498/04 ,  A61K31/538 ,  A61K38/21 ,  A61P31/00 ,  A61P3/00 ,  A61P5/00 ,  A61P37/00 ,  C07D487/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D493/04 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

公开(公告)号：US20120070413A1

公开(公告)日：2012-03-22

申请号：US13308310

申请日：2011-11-30

Applicant: Tae-Seong KIM ,  David Bauer ,  Steven Bellon ,  Alessadro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

Inventor： Tae-Seong KIM ,  David Bauer ,  Steven Bellon ,  Alessadro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

IPC: A61K38/21 ,  A61K31/497 ,  A61K31/5377 ,  A61P35/00 ,  A61K31/437 ,  A61K31/519 ,  A61K31/4184 ,  A61K31/501 ,  A61K31/4709 ,  A61K31/4365

CPC classification number: C07D413/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US08079278B2

公开(公告)日：2011-12-20

申请号：US11989036

申请日：2006-07-21

Applicant: Ning Xi ,  Uchechukwu Wejinya ,  Yantao Shen

Inventor： Ning Xi ,  Uchechukwu Wejinya ,  Yantao Shen

IPC: B01L3/02 ,  G01N1/02 ,  G01L23/10

CPC classification number: B81C99/002 ,  Y10S977/872 ,  Y10T29/49998 ,  Y10T29/53991

Abstract: An end-effector is provided for use on a micro/nano manipulation device. The end-effector is comprised of: a micropump fluidly coupled to a microtube; a piezoelectric sensing structure disposed in the microtube; and a processing circuit electrically coupled to the sensing structure for determining the force of the fluid flowing through the microtube. The end-effector is a closed loop control-enabled micro/nano manipulation system.

Abstract translation: 提供用于微/纳米操纵装置的末端执行器。 末端执行器包括：流体耦合到微管的微型泵; 设置在微管中的压电感测结构; 以及电耦合到感测结构以用于确定流过微管的流体的力的处理电路。 末端执行器是一个闭环控制的微/纳米操纵系统。